Effect of a high-tech autologous immunocyte preparation on the tumor cell microenvironment and survival of rats with C6 glioma (in vivo experimental study)

INTRODUCTION. Glioblastoma (GB) is one of the most lethal human brain tumors. AIM. To study the effect of a preparation of autologous immunocytes with activated TLR/NF-k signaling on the microenvironment of tumor cells (TC) and the survival of rats with C6 glioma. MATERIALS AND METHODS. C6 glioma cells, bone marrow mononuclear cells (BMMC), and outbred Wistar rats were used. Methods: experimental modeling in vivo and in vivo, morphological, immunohistochemical, and enzyme immunoassay. Survival was assessed according to Kaplan – Meier. RESULTS. Ex vivo treatment of mononuclear cells with LPS + dsRNA allows obtaining a high-tech medicinal product (HTMP) characterized by the expression of CD3+ antigens of early activation of B lymphocytes (97.9±7.1 vs. 80.1±6.1 %, P<0.05) and NK cells (91.8±11.1 vs. 72.2±7.7 %, P<0.05), an increase in the number of T-killers in relation to T-suppressor cells (42.8±4.4 vs. 30.5±3.1 %, P<0.05), expression of the early lymphocyte activation antigen CD69 (82.2±18.8 vs. 11.2±2.2, P<0.05), an increase in the content of CD45+ cells (66.3 vs. 42.1%, ) and a decrease in the content of stem cells CD90+ cells (3.3 versus 21.5 %). Transplantation of HTMP into the body of rats with C6 glioma enriches the tumor with markers of CD86+ cells, which is accompanied by an increase in the content of proinflammatory cytokines IL-1, B – IL 6, B – IL18, TNF1. The combination of HTMP and plerixafor increases the survival of experimental animals (74,5 versus 60 days, P<0,0001). CONCLUSION. The complex use of HTMP and plerixafor modifies the OC microenvironment and increases the survival of experimental animals with C6 glioma

1. .